Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A | P37288 | 5/20 | 0.54 |
| ▸ | CYP46A1 | Q9Y6A2 | 7/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL156472 | 0.85 | OPRL1 (0.61) | AVPR1ACYP46A1OPRD1OPRK1OPRM1 | |
| SCHEMBL15945900 | 0.82 | OPRD1 (0.51) | OPRD1OPRK1OPRM1OPRL1HSD17B10 | |
| SCHEMBL3833018 | 0.82 | AVPR1A (0.62) | AVPR1ACYP46A1OPRD1OPRK1OPRM1 | |
| SCHEMBL14902451 | 0.81 | OPRD1 (0.47) | OPRD1OPRK1OPRM1OPRL1HSD17B10 | |
| SCHEMBL23581415 | 0.79 | AVPR1A (0.59) | AVPR1ACYP46A1OPRD1OPRK1OPRM1 | |
| SCHEMBL14263122 | 0.78 | KCNH2 (0.56) | AVPR1ACYP46A1EPHX2 | |
| SCHEMBL27967465 | 0.76 | CYP46A1 (0.48) | AVPR1ACYP46A1OPRD1OPRK1OPRM1 | |
| SCHEMBL18081021 | 0.75 | OPRM1 (0.54) | AVPR1ACYP46A1OPRD1OPRK1OPRM1 | |
| SCHEMBL2951728 | 0.75 | OPRD1 (0.53) | AVPR1ACYP46A1OPRD1OPRK1OPRM1 | |
| SCHEMBL14902503 | 0.75 | OPRD1 (0.49) | OPRD1OPRK1HSD17B10CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249618-A1 | Novel Piperidine Derivatives as Histamine H3 Receptor Ligands for Treatment of Depression | HRH3, HRH1, HRH4 | AVPR1A 209/4885CYP46A1 3920/4885OPRD1 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.